ACM
VRCA icon

Asymmetry Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Asymmetry Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,430
Closed -$1.1M – 40
2019
Q3 		$1.1M Sell
7,430
-5,852
-44% -$652K 2.35% 18
2019
Q2 		$1.54M Buy
13,282
+6,236
+89% +$585K 0.84% 24
2019
Q1 		$762K Buy
7,046
+758
+12% +$87.4K 1.27% 21
2018
Q4 		$512K Sell
6,288
-1,401
-18% -$170K 1.41% 19
2018
Q3 		$1.25M Buy
7,689
+1,689
+28% +$288K 1.15% 32
2018
Q2 		$1.18M Buy
+6,000
New +$1.18M 1.16% 29

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Asymmetry Capital Management's VRCA Position: Q4 2019 in Review

Asymmetry Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q4 2019, closing a stake of 7,430 shares — an estimated $1.1M sold.

Asymmetry Capital Management first reported a position in VRCA in Q2 2018 and held it in 6 quarters. The position peaked at $1.54M in Q2 2019. 52 funds tracked by Wall St. Rank hold VRCA as of Q4 2019.

  • Asymmetry Capital Management reported no remaining Verrica Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Asymmetry Capital Management sold 7,430 Verrica Pharmaceuticals shares in Q4 2019, an estimated $1.1M.
  • Asymmetry Capital Management first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • Asymmetry Capital Management's Verrica Pharmaceuticals position peaked at $1.54M in Q2 2019.
  • 52 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2019.

Based on Asymmetry Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.